This study states that Peramivir, a neuraminidase inhibitor agent with the same mechanism of action as oseltamivir, has been demonstrated to have activity against both influenza A and B viruses, and shorten duration of influenza symptoms for outpatient adults with uncomplicated influenza.13, 14 Several studies previously demonstrated both safety and non-inferiority of peramivir hospitalized patients and outpatients with influenza.13, 15, 16 A multinational, multicenter, double-blind randomized trial in East Asia showed that the duration of influenza symptoms in adult influenza-infected patients treated with a single dose of 300 mg of IV peramivir, or 600 mg of peramivir was non-inferior to that treated with 5-day twice a day oseltamivir. The incidence of severe adverse events by peramivir was similar to oseltamivir.13 de Jong and colleagues conducted a trial in hospitalized patients with suspected influenza randomized to 5-day treatment with intravenous peramivir (600 mg once daily) or placebo; all received the institution’s standard of care treatment. That also showed that no difference in median time to clinical resolution between the two groups. However, there was a trend toward a shorter time to clinical resolution in ≥4 of 5 vital sign abnormalities (temperature, oxygen saturation, respiration rate, heart rate, and systolic blood pressure) for 24 hours, among those who required intensive care who received peramivir. 

Reference link-